Volume 28, Number 10—October 2022
Research
SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA
Table 1
Descriptive statistics for matched case-patients and controls for the conditional logistic regression model for study of SARS-CoV-2 vaccine breakthrough during the emergence period of the Omicron variant, New York, USA*
Demographic group | No. (%) |
|||||||
---|---|---|---|---|---|---|---|---|
Analysis 1, main |
Analysis 2, by age |
Analysis 3, vaccinated only |
||||||
Controls | Case-patients | Controls | Case-patients | Controls | Case-patients | |||
Age, y | ||||||||
0–4 | 4 (1.5) | 4 (1.5) | 9 (2.9) | 4 (1.3) | 0 | 0 | ||
5–11 | 4 (1.5) | 4 (1.5) | 7 (2.3) | 9 (2.9) | 0 | 0 | ||
12–17 | 11 (4) | 11 (4.0) | 15 (4.9) | 16 (5.2) | 3 (2.3) | 3 (2.3) | ||
18–29 | 55 (20.2) | 55 (20.2) | 39 (12.6) | 85 (27.5) | 23 (17.8) | 23 (17.8) | ||
30–49 | 95 (34.9) | 95 (34.9) | 85 (27.5) | 95 (30.7) | 49 (38.0) | 49 (38.0) | ||
50–69 | 71 (26.1) | 71 (26.1) | 96 (31.1) | 69 (22.3) | 40 (31.0) | 40 (31.0) | ||
70–89 | 31 (11.4) | 31 (11.4) | 52 (16.8) | 30 (9.7) | 14 (10.9) | 14 (10.9) | ||
>90 |
1 (0.4) |
1 (0.4) |
6 (1.9) |
1 (0.3) |
0 |
0 |
||
Sex | ||||||||
M | 141 (51.8) | 147 (54.0) | 155 (50.2) | 153 (49.5) | 65 (50.4) | 77 (59.7) | ||
F | 129 (47.4) | 123 (45.2) | 152 (49.2) | 155 (50.2) | 63 (48.8) | 52 (40.3) | ||
Unknown |
2 (0.7) |
2 (0.7) |
2 (0.6) |
1 (0.3) |
1 (0.8) |
0 |
||
Region | ||||||||
Capital | 107 (39.3) | 107 (39.3) | 121 (39.2) | 121 (39.2) | 47 (36.4) | 47 (36.4) | ||
Central New York | 17 (6.2) | 17 (6.2) | 18 (5.8) | 18 (5.8) | 10 (7.8) | 10 (7.8) | ||
Finger Lakes | 7 (2.6) | 7 (2.6) | 9 (2.9) | 9 (2.9) | 3 (2.3) | 3 (2.3) | ||
Long Island | 25 (9.2) | 25 (9.2) | 27 (8.7) | 27 (8.7) | 12 (9.3) | 12 (9.3) | ||
Mid-Hudson | 42 (15.4) | 42 (15.4) | 47 (15.2) | 47 (15.2) | 26 (20.2) | 26 (20.2) | ||
Mohawk Valley | 10 (3.7) | 10 (3.7) | 18 (5.8) | 18 (5.8) | 4 (3.1) | 4 (3.1) | ||
New York City | 4 (1.5) | 4 (1.5) | 6 (1.9) | 6 (1.9) | 1 (0.8) | 1 (0.8) | ||
North Country | 38 (14.0) | 38 (14.0) | 39 (12.6) | 39 (12.6) | 20 (15.5) | 20 (15.5) | ||
Southern Tier | 14 (5.1) | 14 (5.1) | 16 (5.2) | 16 (5.2) | 2 (1.6) | 2 (1.6) | ||
Western New York |
8 (2.9) |
8 (2.9) |
8 (2.6) |
8 (2.6) |
4 (3.1) |
4 (3.1) |
||
Vaccination status | ||||||||
Unvaccinated | 154 (56.6) | 82 (30.1) | 175 (56.6) | 78 (25.2) | 0 | 0 | ||
Vaccinated <90 d | 3 (1.1) | 4 (1.5) | 3 (1.0) | 5 (1.6) | 2 (1.6) | 2 (1.6) | ||
Vaccinated >90 d | 115 (42.3) | 186 (68.4) | 131 (42.4) | 226 (73.1) | 127 (98.4) | 127 (98.4) | ||
Pfizer vaccine | 64 (23.5) | 113 (41.5) | 69 (22.3) | 135 (43.7) | 64 (49.6) | 82 (63.6) | ||
Moderna vaccine | 43 (15.8) | 66 (24.3) | 49 (15.9) | 82 (26.5) | 48 (37.2) | 41 (31.8) | ||
Janssen vaccine | 11 (4) | 11 (4.0) | 16 (5.2) | 14 (4.5) | 17 (13.2) | 6 (4.7) | ||
Unboosted | 250 (91.9) | 211 (77.6) | 281 (90.9) | 210 (68.0) | 108 (83.7) | 88 (68.2) | ||
Boosted <90 d | 18 (6.6) | 49 (18.0) | 25 (8.1) | 76 (24.6) | 18 (14) | 37 (28.7) | ||
Boosted >90 d | 2 (0.7) | 9 (3.3) | 2 (0.6) | 20 (6.5) | 1 (0.8) | 3 (2.3) | ||
Pfizer booster | 11 (4.8) | 41 (15.4) | 13 (4.5) | 68 (22.7) | 10 (7.8) | 33 (25.6) | ||
Moderna booster | 9 (3.3) | 17 (7) | 14 (4.5) | 281 (9.4) | 9 (7.0) | 7 (5.4) |
*Presence (case-patient) or absence (control) of Omicron was used as the basis for matching. Janssen vaccine, Janssen/Johnson & Johnson (https://www.jnj.com); Pfizer vaccine/booster, Pfizer-BioNTech (https://www.pfizer.com); Moderna vaccine/booster, Moderna (https://www.modernatx.com).